Positive high-level results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca’s ...

Ligand Pharmaceuticals (Nasdaq: LGND) has entered into a royalty financing agreement with Castle Creek Biosciences, providing ...

California-based biotech Eikon Therapeutics today announced the initial closing of a $350.7 million Series D financing. Since ...

Shares of Sweden’s immune-oncology firm Alligator Bioscience were up almost 160% at 0.11 kronor by early afternoon today, ...

Swiss biotech company Idorsia has revised its collaboration terms with Viatris, reducing its financial commitment to the ...

Candel Therapeutics (Nasdaq: CADL) has released final data from a Phase II trial of its investigational immunotherapy, ...

Cardiovascular diseases specialist Kiniksa Pharmaceuticals International has announced updates to its pipeline alongside ...

Israel-headquartered Teva Pharmaceutical Industries’ US subsidiary and France’s and Medincell announced that the supplemental ...

Privately-held BridGene Biosciences has announced a strategic collaboration and licensing agreement with Japan’s Takeda. The ...

US pharma major Eli Lilly has announced a deal with San Diego-based Organovo Holdings, a biotech focused on developing novel ...

US drugmaker Eli Lilly has launched 7.5mg and 10mg Zepbound (tirzepatide) single-dose vials for the treatment of obesity.